BriaCell Therapeutics Corp. (BCTX) rose 4.16% to trade at $12.77, up $0.51, following news of a collaboration with Memorial Sloan Kettering Cancer Center's Therapeutics Accelerator and the expansion of its Phase 3 pivotal study (NCT06072612).
The partnership supports Bria-OTS+™ and Bria-BRES+™ programs through manufacturing, IND preparation, and clinical protocol development. The Phase 3 trial now includes three additional U.S. cancer centers, Dartmouth Cancer Center, Cedars-Sinai Medical Center, and Winship Cancer Institute of Emory University, bringing the total to 79 sites across 23 states, with top-line results expected in H1 2026.
On Tuesday, BCTX opened at $12.42, hit a high of $12.96, and a low of $12.42, compared to a previous close of $12.26 on the NASDAQ. Trading volume reached above average levels. The stock's 52-week range is $0.84 - $13.38.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.